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Abstract: The outbreak of novel coronavirus disease (2019-nCoV or COVID-19) is responsible for
severe health emergency throughout the world. The attack of severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is found to be responsible for COVID-19. The World Health Organization
has declared the ongoing global public health emergency as a pandemic. The whole world fights
against this invincible enemy in various capacities to restore economy, lifestyle, and safe life. Enormous
amount of scientific research work(s), administrative strategies, and economic measurements are
in place to create a successful step against COVID-19. Furthermore, differences in opinion, facts,
and implementation methods laid additional layers of complexities in this battle against survival.
Thus, a timely overview of the recent, important, and overall inclusive developments against this
pandemic is a pressing need for better understanding and dealing with COVID-19. In this review, we
have systematically summarized the epidemiological studies, clinical features, biological properties,
diagnostic methods, treatment modalities, and preventive measurements related to COVID-19.
Keywords: coronavirus; COVID-19; controversies; biology; diagnosis; treatment; prevention;
technology; data; alternatives
1. Introduction
The emergence and spread of 2019 novel coronavirus (2019-nCoV) or the severe acute respiratory
syndrome (SARS) coronavirus 2 (SARS-CoV-2) has threatened global public health. The coronavirus
disease 2019 (COVID-2019), which is a transmission of SARS-CoV-2 to humans, was reported first
in Wuhan, Hubei province, China in December 2019. Later, COVID-19 rapidly spread worldwide
creating a pandemic as there have been around 15,656,884 reported cases and 636,576 reported deaths
to date (24 July 2020) affecting 213 countries and territories around the world and two international
conveyances (https://www.worldometers.info/coronavirus/). North America, South America, and Asia
are the most affected (maximum number of cases) continents by this pandemic so far (https://
www.worldometers.info/coronavirus/, data accessed on 24 July 2020) (Figure 1A). In spite of rapid
development of knowledge, precautionary measurements, and clinical trials, researchers, regulatory
bodies, and government administrations are facing a great challenge globally in various aspect to
prevent COVID-19 pandemic. The present situation is leading us to a still unknown future and
conflicting paradox in the battle against SARS-CoV-2. Further, a plethora of documents have been
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published on “coronavirus” and “coronavirus disease” (year-wise keyword search for last 10 years
in PubMed on 24 July 2020) research, where a maximum and a very large number of results were
obtained in 2020 on both the keywords in comparison to previous years (Figure 1B). Nature Index has
also reported a hugely increasing global research publishing phenomenon on COVID-19 pandemic
as evidenced by 66,883 articles and 19,420 preprints (https://www.natureindex.com/news-blog/the-
top-coronavirus-research-articles-by-metrics). A thorough and cumulative scientific knowledge
about the progress against COVID-19 amid various conflicts and controversies is the need of the
time to set a clear directive in this battle. Through this review article, we provide an overview of
updated and rapidly evolving progress against COVID-19 pandemic including various conflicts to
the readers in a comprehensive manner. Considering this, we have summarized diverse research
areas covering the current known biological properties of SARS-CoV-2, diagnostic tools for detection,
therapeutic measurements for possible treatment, and prevention techniques to stop further spreading
of this pandemic.
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2. Origin, Transmission, and Symptoms
2.1. Origin
2.1.1. Genesis, Structure, and Features
Coronaviru es (s bfamily: Coronavirinae, family: Coronaviridae, order: Nidovirales) are
enveloped single stranded positive sense RNA genomes that range in size from 26 to 32 kilobases [1,2].
Coronavirus consists of four structural proteins: the nucleocapsid, envelope, membrane, and spike
forming a core-shell morphology (Figure 2), whose diameter is in the range from 60 nm to 140 nm
with spike like projections on its surface [2–4]. The name, coronavirus (Latin: Corona = Crown) came
out due to the presence of a cr wn or the sun’s corona-like spike (S) glycoprotein on viral surface
forming club-shaped protrusio s, which is also evide ced through the electron microscope [2–4].
This transm mbrane spike (S) glycoprotein on viral surface me iates the entry into host cells, f rming
homotrimers protruding from the viral surface [5]. The receptor binding domain (RBD) in the spike
(S) glycoprotein is the most mutable part of the coronavirus genome leading to generation of new
properties and ability of virus to infect new cell types or even new species [6]. Based on phylogenetic
relationships and genomic structures, the subfamily Coronavirinae is divided into four genera (α-CoV,
β-CoV, γ-CoV, and δ-CoV). α-CoV and β-CoV only infect mammals, whereas γ-CoV and δ-CoV infect
generally birds and sometimes even infect mammals. β-CoV and γ-CoV are responsible for respiratory
diseases in humans and gastroenteritis in animals [2,7]. Presence of four corona viruses (HKU1, NL63,
229E and OC43) have been found in human circulation which are generally cause mild respiratory
disease [8].
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adult COVID-19 patients in Wuhan, China. Its morphology was analyzed by negatively stained 
sample under transmission electron microscopy (TEM) [12]. Zhu et al. [12] made a conclusion based 
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SL-CoVZC45, MG772933.1). These observations are similar to the overall structure of Coronaviridae 
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protease (Mpro) and its complex with an α-ketoamide inhibitor was used to provide some knowledge 
about the drug target for COVID-19 [14]. This Mpro enzyme is essential one along with the papain-
like protease(s) for processing the viral RNA translated polyproteins. Thus, inhibition of this enzyme 
may block the viral replication. The three-dimensional crystal structure, at 1.75 Å resolution, of the 
SARS-CoV-2 Mpro is highly similar to the SARS-CoV Mpro, due to the 96% sequence identity. 
Dimerization (necessary for catalytic activity) of the Mpro is regulated by Domain III (residues 198 to 
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2.1.2. SARS-CoV-2
The 2019-nCoV is phylogenetically closely related to bat SARS-like coronaviruses, hence name
SARS-CoV-2 and belongs to β-CoV genus lineage B [9]. Regarding pathogenicity and transmissibility,
SARS-CoV-2 may differ from other known SARS-CoV due to a significant change in its spike
glycoproteins (ORF8, and ORF3b) [10]. Doremalen et al. [11] showed that the SARS-CoV-2 virus
remained viable in aerosols (<5 µm) for at least up to 3 h and was more stable on plastic and stainless
steel than on copper and cardboard. SARS-CoV-2 was first identified from the samples (cultured
human airway epithelial cells along with the virus from isolated bronchoalveolar lavage fluid) of adult
COVID-19 patients in Wuhan, China. Its morphology was analyzed by negatively stained sample
under transmission electron microscopy (TEM) [12]. Zhu et al. [12] made a conclusion based on TEM
ultra-structural image of SARS-CoV-2 virus particles. This follows as (i) it is generally spherically
shaped with a diameter ranges from 60 to 140 nm, (ii) it has an envelope with quite distinctive 9 to
12 nm protein spikes, and (iii) it has genetic material which matched to the genome from lineage B
of the genus β-CoV—showing more than 85% identity with a bat SARS-like CoV (bat-SL-CoVZC45,
MG772933.1). These observations are similar to the overall structure of Coronaviridae family viruses.
TEM image of an isolate from the first United States case of COVID-19 is also evidenced the spherically
shaped viral particles (colorized blue) containing cross-sections through the viral genome (black
dots) [13]. The crystal structures of the unliganded SARS-CoV-2 main protease (Mpro) and its complex
with an α-ketoamide inhibitor was used to provide some knowledge about the drug target for
COVID-19 [14]. This Mpro enzyme is essential one along with the papain-like protease(s) for processing
the viral RNA translated polyproteins. Thus, inhibition of this enzyme may block the viral replication.
The three-dimensional crystal structure, at 1.75 Å resolution, of the SARS-CoV-2 Mpro is highly similar
to the SARS-CoV Mpro, due to the 96% sequence identity. Dimerization (necessary for catalytic activity)
of the Mpro is regulated by Domain III (residues 198 to 303) mainly through a salt-bridge interaction
between Glu290 of one protomer and Arg4 of the other.
2.2. History
Like SARS-CoV-2, world also has seen an outbreak of worldwide pandemic and a large-scale fatal
swine disease during the past two decades because of three other zoonotic (transmitted from animals
to human) coronaviruses, such as SARS in 2003, Middle East Respiratory Syndrome (MERS) in 2012,
and Swine Acute Diarrhea Syndrome (SADS) in 2017. Surprisingly, these viruses have been originated
from bats, a natural source of various other highly lethal zoonotic viruses (such as Hendra, Nipah,
Ebola, and Marburg viruses). SARS and SADS viruses were claimed to be originated in China [15,16].
Based on these facts, scientists including Chinese research group from Wuhan (primary epicenter of
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COVID-19) also warned further possible coronavirus outbreaks from bats and with a high probability
that outbreak will occur in China [17].
2.3. Transmission
2.3.1. Unknown Intermediary Host
Both SARS-CoV and MERS-CoV bat β-coronaviruses crossed over to humans through
an intermediary host, which was palm civet cats in the Guangdong province of China (SARS-CoV,
in 2002–2003, mortality rate 11%) and dromedary camels in Saudi Arabia (MERS-CoV, in 2012, fatality
rate 34%), respectively [18]. In the case of COVID-19, the virus was transmitted to human from bats,
but the intermediary host animal(s) are not yet known. A study claimed that the intermediary host
animal is pangolin due to the following findings on Pangolin-CoV, SARS-CoV-2, and BatCoV RaTG13
viruses: (i) At the whole-genome level, both Pangolin-CoV and SARS-CoV-2 share 91.02% similarity
among them, (ii) Pangolin-CoV and SARS-CoV-2 are reported to be the second closest relative to each
other than to BatCoV RaTG13, (iii) In the receptor binding domain (RBD) of spike glycoprotein, five key
amino acid residues involved in the interaction with human angiotensin converting enzyme 2 (ACE2)
of Pangolin-CoV and SARS-CoV-2 are consistent, and (iv) Only SARS-CoV-2 contains a potential
cleavage site for furin proteases unlike both Pangolin-CoV and RaTG13 [19]. It was also concluded
that the transmission of human SARS-CoV-2 virus from bat may include more than one intermediary
host including pangolins [20].
2.3.2. Human to Human Transmission
Similar to SARS-CoV, the 2019-nCoV is reported to have the capability to transmit efficiently
among humans due to familial cluster of pneumonia [9]. Several cases were reported person-to-person
transmission of this virus not only through family settings, but were also in hospital and infected
travelers [9,21]. Person-to-person transmission of the SARS-CoV-2 infection is occurred via airborne
droplets to the nasal mucosa in closed environments, close contact between people, unwashed hands,
and touching contaminated surfaces with less possibilities. Within the incubation period ranges from 2
to 14 days in general, SARS-CoV-2 may replicate locally in cells of the ciliated epithelium resulting
cell damage and inflammation. Primarily, respiratory secretions of any infected person are used to
diagnose the presence of virus by special molecular tests including normal/low white cell counts with
elevated C-reactive protein (CRP) [18]. Additionally, abnormal computerized tomographic (CT) chest
scan is also proved to be helpful to diagnose any infected person even for those with no symptoms or
mild disease [18]. The SARS-Cov-2 showed lower mortality but faster spreading than SARS-CoV and
MERS-CoV. Isolation of SARS-CoV-2 from oral swabs, bronchoalveolar lavage fluid, and stool proved
them to be highly contagious [22,23].
2.3.3. Receptor-Mediated Cellular Entry
SARS-CoV-2 infects human by interacting with a functional receptor, metallopeptidase named
angiotensin converting enzyme 2 (ACE2), for its successful cellular entry (Figure 2) [22,24]. Crystal
structure of the C-terminal domain of spike protein in complex with human ACE2 (hACE2) revealed an
overall similar binding mode as that of SARS-CoV with hACE2 [24]. It was determined that 2019-nCoV
uses ACE2 as a cellular entry receptor in human, Chinese horseshoe bats, civets, and pigs but not for
mice and cells without ACE2 protein expression capability [22]. Other coronavirus receptors, such as
aminopeptidase N and dipeptidyl peptidase 4 do not play any role for cellular entry of 2019-nCoV [22].
Previous studies revealed that almost all human organs are known to have ACE2 mRNA, though the
protein expression of ACE2 mRNA was largely unknown. Such ACE2 receptor is found to be present
in arterial and venous endothelial cells, arterial smooth muscle cells in the lungs, stomach, small
intestine, liver bile ducts, colon, skin, kidney parietal epithelial cells, lymph nodes, and in the brain [25].
The surface of lung alveolar epithelial cells and enterocytes of the small intestine also express ACE2
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protein allowing them to be infected by SARS-CoV-2 [25]. The tissues of the upper respiratory tract
are not the primary site of entrance for SARS-CoV, as oral and nasal mucosa and nasopharynx did
not show ACE2 expression on the surface of epithelial cells, rather upper respiratory tract might be
susceptible to secondary infections from the infected lower respiratory tract. Lower lungs may show
higher opacity in the CT scans due to its more ACE2 expression [26]. Higher viral loads have been
recorded in the nose than the in throat, with similar viral loads seen in asymptomatic and symptomatic
patients [27].
2.4. Symptoms and Impact
Coronaviruses generally are found to cause acute and chronic respiratory, enteric, and central
nervous system diseases in humans as well as in other animals. The symptoms of a COVID-19 patient
are usually fever, cough, sore throat, breathlessness, fatigue, and feeling of discomfort. For most of the
people, it is found mild. For elderly and the patient with comorbidities may develop pneumonia, acute
respiratory distress syndrome (ARDS), and multi-organ dysfunction leading to death. Many infected
people are found to be asymptomatic causing a problem for early detection and controlling the spread
of disease. Mortality rate estimated by the World Health Organization (WHO) (as of 3 March 2020)
is 3.4% (https://www.worldometers.info/coronavirus/coronavirus-death-rate/). Further, speculation
about the association of human coronaviruses with more serious human diseases (such as multiple
sclerosis, hepatitis, or enteric disease in infants) are still under question due to no proper evidence [8].
3. Diagnostic Modalities
In absence of any approved therapeutics or vaccines for the treatment of COVID-19, WHO has
promoted “test, isolate, and trace” method as a preventive measure. Thus, early, rapid, and accurate
diagnosis of COVID-19 patients is becoming very crucial to control the sources of infection and
to prevent further community spread. With a gradual understanding of biological properties of
SARS-CoV-2, various diagnostic methods and device strategy with point of care facilities have been
developed for COVID-19 detection worldwide. A summary of various diagnostic methods (Table 1)
are presented for the COVID-19 detection. Various countries approved and implied different testing
methods according to the regulation of their own health agencies based on situation and availabilities.
Below subsections are summarized the recent developments on diagnostic methods based on (i) nucleic
acid, (ii) protein, (iii) chest scan and (iv) autopsy.
Table 1. Various detection methods implied for COVID-19 diagnosis.
Test Method Sample/Organ
Nucleic acid-based
detection
1.Polymerase chain reaction
2. Isothermal nucleic acid
amplification
3. CRISPR-Cas
1. Nasal (Nasopharyngeal)/Throat
(Oropharyngeal) Swab
2. Blood (Serological test)
3. Fecal swab
Protein-based detection Viral antibody levels
1. Blood (Serological test)
2. Respiratory swab
3. Fecal
Chest scan (auxiliary test) 1. X-ray2. Computed tomography Lung
Autopsy Surgical (Post-mortem examination) Corpse
3.1. Nucleic Acid-Based Detection
Nucleic acid-based detection strategy has been widely used against detection of various diseases,
including coronavirus and recent COVID-19. In this section, we review some nucleic acid-based
detection methods that are commonly being employed for the diagnosis of COVID-19.
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3.1.1. Polymerase Chain Reaction
Polymerase chain reaction (PCR) is an enzymatic method widely used in molecular biology to
make millions to billions of copies of a specific DNA sample [28]. This method involves following
steps in a series or cycles of temperature changes: (i) Denaturation: separating the two strands of the
DNA containing the gene segment with the application of heat, (ii) Annealing-marking gene segment
of each strand of DNA with a primer, (iii) Primer extension: using a DNA polymerase to assemble
a copy alongside each segment, and (iv) Repeat: continuously copy the copies [28]. Various PCR-based
methods are an indispensable, common, and rapid techniques for scientist to amplify a minute nucleic
acid sample to a large enough amount for a number of applications [29]. Due to high sensitivity and
high sequence specificity, the PCR-based method has been used as a routine and reliable technique for
detecting coronaviruses. Coronavirus is a RNA virus, so in general reverse transcriptase-PCR (RT-PCR)
method is implied as follows: coronavirus RNA is transcribed into cDNA by reverse transcription,
then the PCR is performed on cDNA, and finally detection of PCR product through specific detection
method(s) (gel visualization and sequencing) [30,31].
Real-time: Real-time reverse transcriptase-PCR (RT-PCR) detection method is evolved as a
common platform for detection of all kinds of coronaviruses due to its low cost per test, less
time-consuming process and more sensitive than the conventional RT-PCR assay [32,33]. The whole
genome sequence of SARS-CoV-2 enabled to develop PCR-based kits to diagnose COVID-19 in
laboratory and clinical settings [34–39]. Corman et al. [34] developed a robust diagnostic methodology
considering the SARS-related virus sequences available in GenBank. A close genetic relatedness to
the 2003 SARS-CoV and synthetic nucleic acid technology helped this process to design and validate
such strategy without using any virus isolates and samples from infected person. Such a technique
can successfully discriminate 2019-nCoV from SARS-CoV. This approach provided the first version
of the diagnostic protocol to the WHO from exclusivity testing on 75 clinical samples (13 January
2020). A real-time RT-PCR based test is found to be more sensitive than radiological test for pediatric
patients [36]. Pediatric patients with milder symptoms, showed no clear clinical signs or chest X-ray
findings but their real-time RT-PCR exhibited positive results. Further, in this report, real-time RT–PCR
showed positive results in rectal swab-testing but negative results in nasopharyngeal swab-testing for
eight out of ten pediatric patients suggesting shedding of virus in the gastrointestinal tract and a possible
fecal-oral transmission. Wang’s group [37] reported that the RT-PCR based findings using different
types of clinical specimens collected from 82 infected individuals. In their study, it was found that
viral loads were significantly correlated among 30 pairs of throat swab and sputum samples. Overall,
real-time RT-PCR based method enables developing a high-throughput testing for rapid, on-demand,
low-cost, reliable, quantitative detection technique against COVID-19 in clinical settings [39].
Probe free: A team of Indian Institute of Technology, Delhi, India reported first probe-free real
time PCR assay for COVID-19 detection (http://www.iitd.ac.in/content/icmr-approves-probe-free-
covid-19-detection-assay-developed-iit-delhi-0). They have used comparative sequence analyses to
identify unique regions (short stretches of RNA sequences) in the SARS COV-2 genome, which are not
present in other human coronaviruses. In this highly sensitive assay, primers can specifically target
unique regions (conserved in over 400 fully sequenced) of COVID-19 genomes, which was reported
after extensive optimization using synthetic DNA constructs followed by in vitro generated RNA
fragments. Indian Council of Medical Research has approved this technique as it does not require any
fluorescent probes (thus low-price) but still useful for high throughput testing.
3.1.2. Isothermal Nucleic Acid Amplification
Isothermal amplification of nucleic acids is a rapid, efficient, and alternative amplification technique
than PCR. This process can be applied at a constant temperature without any thermos-cycling apparatus,
unlike in the case of PCR [40,41]. The isothermal amplification technique can be performed in water bath,
on the cell surface, or even inside living cells, making it a superior technique over PCR [40,41]. Based on
reaction kinetics of isothermal nucleic acid amplification, it is divided to exponential amplification,
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linear amplification, and cascade amplification. These are further sub-divided into transcription
mediated amplification, nucleic acid sequence-based amplification, signal mediated amplification
of RNA technology, strand displacement amplification, rolling circle amplification, loop-mediated
isothermal amplification of DNA, isothermal multiple displacement amplification, helicase-dependent
amplification, single primer isothermal amplification, and circular helicase-dependent amplification,
based on the developments in molecular biology of DNA/RNA synthesis [40,41]. Furthermore, the use
of microfluidic chips, capillary platforms, and test paper with isothermal amplification technique has
been developed for single-cell or single-molecule analysis. Among these, loop-mediated isothermal
amplification (LAMP) has been implied successfully for coronavirus detection [42–45]. LAMP technique
can amplify target nucleic acid sequence using two or three sets of primers and a polymerase at a
constant temperature (~60–65 ◦C) [46–48]. In comparison to PCR-based technique, LAMP can produce
considerably higher amount of DNA with high strand displacement and replication activity due to the
use of additional pair of “loop primers”.
Park et al. [46] developed reverse transcription LAMP (RT-LAMP) assay(s) to detect genomic
RNA of SARS-CoV-2. These RT-LAMP assays (in combination with leuco crystal violet colorimetric
detection method) can detect as low as 100 copies of SARS-CoV-2 RNA within 30 min. These RT-LAMP
assays were highly specific towards SARS-CoV-2 compared to other human coronaviruses (hCoV-229E,
hCoVOC43, MERS-CoV, and SARS-CoV). Yu et al. [49] also developed a rapid and sensitive isothermal
LAMP based method (iLACO) for the detection of COVID-19 virus RNA or cDNA samples. In this
method, iLACO was used to amplify a fragment of the ORF1ab gene using 6 primers, which was
proved to be specific for SARS-COV-2 species (i.e., low chance for false positives) in comparison
to the sequences of 11 related viruses by the help of online tool Primer-BLAST (including 7 similar
coronaviruses, 2 influenza viruses and 2 normal coronaviruses). iLACO can detect synthesized RNA
equivalent to 10 copies of 2019-nCoV (performance is comparable to Taqman based qPCR detection
method), where reaction time varied from 15–40 min based on virus load in the collected samples.
Another LAMP-based colorimetric detection method was reported to identify SARS-CoV-2 virus
RNA from purified RNA or cell lysis (without an RNA purification step) [48]. The sensitivity of this
portable method is equivalent to a commercial RT-qPCR test with only heating and visual inspection.
Zhu et al. [47] demonstrated a successful and accurate diagnosis of COVID-19 using one-step RT-LAMP
coupled with nanoparticles-based biosensor (NBS) assay (RT-LAMP-NBS) within approximately 1 h
(from sample collection to result interpretation). They have employed two designed LAMP primer
sets (F1ab-RT-LAMP and np-RT-LAMP), heating block (to maintain a constant temperature at 63 ◦C),
a real-time turbidity (LA-320C) and visual detection reagents (VDR) in addition to NBS interpretation
to simultaneously amplify and detect genes of SARS-CoV-2 in a “one-step” and “single-tube” reaction.
The sensitivity of SARS-CoV-2 RT-LAMP-NBS was 12 copies (each of detection target) per reaction,
whereas no cross-reactivity was observed for all pathogens of non-SARS-CoV-2 (virus, bacteria,
and fungi). The RT-LAMP-NBS assay showed 100% the analytical sensitivity of SARS-CoV-2 for
oropharynx swab samples of clinically diagnosed COVID-19 patients and 100% specificity for clinical
samples collected from non-COVID-19 patients.
3.1.3. CRISPR Diagnostics
CRISPR-Cas (clustered regularly interspaced short palindromic repeats-CRISPR associated) is an
adaptive immune system, which was discovered first in Escherichia coli in 1987 and later also in other
bacteria species. These are found predominantly in archaea (87% of genomes) than in bacteria (50% of
genomes) [50,51]. Being an immune system of archaea and bacteria, CRISPR and CRISPR-associated
proteins deliver protection against invasive nucleic acids (such as DNA, or RNA from phages, plasmids,
and other exogenous DNA elements) [50,51]. Scientists later exploited this immune responsive system
by reengineering to target parts of genetic material for precise genetic alterations of any particular
cellular type, which is the basis of CRISPR therapeutic and diagnostic platforms for human [52,53].
This adaptive immune system is also widely used as a tool for SARS-CoV-2 detection. CRISPR
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associated enzyme Cas13 has already been utilized for rapid and portable sensing for successful
RNA-targeting [54]. A Specific High-sensitivity Enzymatic Reporter unLOCKing (SHERLOCK)
platform was developed by combining isothermal preamplification with Cas13 to detect single molecules
of RNA or DNA for Dengue or Zika virus [55]. An updated SHERLOCK protocol has been reported for
multiplexable, portable, rapid, and quantitative COVID-19 detection (https://broad.io/sherlockprotocol),
which can target sequences in a range between 20 and 200 aM (10–100 copies per microliter of input).
Another development of accurate CRISPR-Cas12-based lateral flow assay able to detect SARS-CoV-2
with 95% positive predictive agreement and 100% negative predictive agreement from respiratory
swab RNA extracts (less than 40 min) [56]. Another newly developed method, SARS-CoV-2 DNA
Endonuclease-Targeted CRISPR Trans Reporter (DETECTR), was found to perform simultaneous reverse
transcription and isothermal amplification by (i) RT-LAMP for RNA extracted (for nasopharyngeal or
oropharyngeal swabs), (ii) Cas12 detection of predefined coronavirus sequences, and (iii) cleavage of a
reporter molecule confirms, which detects the virus [56]. A FnCas9 Editor Linked Uniform Detection
Assay (FELUDA) was developed for detecting nucleotide sequences, classifying nucleobase identity,
and inferring zygosity [57]. FELUDA is able to distinguish clear signatures of SARS-CoV-2 sequence in
synthetic DNA within one hour using a specific ribonucleoprotein (RNP) from non-specific RNP (such
as H1N1 or HBB). FELUDA can also clearly distinguish between two SARS-CoV-2 and SARS-CoV-1
sequences. This approach further can be developed as lateral flow assay on a paper strip to distinguish
SARS-CoV-2 synthetic DNA using SARS-CoV-2 specific RNP.
3.2. Protein-Based Detection
Protein-based testing has become as an alternative and additive detection strategy in addition
to nucleic-acid based testing methods for coronavirus [58]. In response to any infected viral protein
antigens, antibodies (i.e., a blood protein produced in response to and counteracting a specific
antigen) are generated in patient’s body resulting a very specific antigen-antibody (Ag-Ab) serological
interaction. Detection of this specific antibody level(s) due to the SARS-CoV-2 infection can be useful for
surveillance of COVID-19 pandemic. This indirect serological test opens up wide range of possibilities,
such as, (i) successful detection of asymptomatic patients, (ii) creating large a window of testing
time even with a gradual decrease of viral load, (iii) protect community transmission due to false
negative results by other methods, and (iv) proper guidance for individual quarantine period [59–66].
Kwok-Yung Yuen’s group [61] successfully detected antibodies generated in response to SARS-CoV-2
viral proteins at the time when the detection of the viral proteins become difficult due to gradual
declining trend of viral load(s). Serological test using enzyme-linked immunosorbent assay (ELISA)
for antibodies (immunoglobulin M, IgM and immunoglobulin G, IgG) is more confirmatory and
unreliable results from oral swabs for 2019-nCoV detection [62]. This test can be applied for respiratory,
blood, or fecal samples. Guo et al. [63] conducted a COVID-19 profiling study on early humoral
response based on IgA, IgM, and IgG response. This study found that IgM and IgA antibody were
detected 5 days, while IgG was detected 14 days after symptom onset, with a positive rate of 85.4%,
92.7%, and 77.9%, respectively [63]. The detection of IgM by ELISA was found more efficient than
that of qPCR after 5.5 days of symptom onset [63]. A successful immunological field-effect transistor
(FET)-based biosensing device was developed for detecting SARS-CoV-2 in clinical samples, where
the sensor was developed by conjugating a specific antibody against SARS-CoV-2 spike protein to
graphene sheet coated FET [64]. This rapid diagnostic device for SARS-CoV-2 antigen requires no
sample pre-treatment or labelling. This is a highly-sensitive detection method for the SARS-CoV-2 spike
protein at concentrations of 1 fg/mL in phosphate-buffered saline and 100 fg/mL in clinical transport
medium, 1.6 × 101 pfu/mL in culture medium and 2.42 × 102 copies/mL in clinical samples. The false
positive results in serological tests for COVID-19 is a concern due to the presence antibodies generated
against other coronaviruses (such as for common cold) irrespective of the presence of SARS-CoV-2
antibodies. Recently, researchers have got a high frequency of cross-reactivity in plasma samples
from 15 COVID-19 patients against the S protein of SARS-CoV-2 and SARS-CoV [65]. However, more
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accurate antibody-based detection method can be made with additional features of infected patient in
serological test, such as (i) combined (IgM and IgG) antibody assay rather than a single antibody test,
(ii) more number of testing, (iii) report of elevated levels of C-reactive protein, D-dimer, lymphocytes,
leukocytes, or blood platelets [66].
3.3. Chest Scan-Auxiliary Test
There are growing concerns regarding the COVID-19 testing despite of huge efforts in this direction.
Due to sudden outbreak and a huge increase of COVID-19 cases, a sufficient number of COVID-19 test
kits are unavailable in hospitals and healthcare centers. Further, an automatic detection system with a
quick diagnostic capability could be an alternative or auxiliary method to prevent community spreading
of COVID-19. In this situation, most countries have recommended the RT-PCR-based methods as the
standard technique for COVID-19 diagnosis. Serological tests are also considered to be the primary
technique for COVID-19 detection. However, small hospitals, health centers in sub-urban and village
areas, even private hospitals in sub-urban area may not have an approved RT-PCR testing center
or PCR testing infrastructure facilities. On the other hand, chest-scan, a routine technique implied
for prominent pneumonia pattern, has been evolved as useful non-invasive technique for COVID-19
detection [67]. Both chest X-ray and computed tomography (CT)-scan were successful to distinguish
the manifestations of typical pneumonia in the case of MERS-CoV and SARS-CoV infection [68,69].
These scans have helped to diagnoses suspected person to isolate and treat more quickly, even when the
RT-PCR based test did not respond properly. Such tests have proven lung histology (lung damage or
holes/honeycomb-like appearance) of COVID-19 patients [70]. Thus, chest-scan is useful for suspected
COVID-19 patients with negative RT-PCR result.
3.3.1. X-ray
X-rays, a form of high-energy electromagnetic radiation, are shorter wavelengths than UV rays and
longer wavelengths than gamma rays. X-ray machines are widely available sophisticated diagnostic
imaging technique for body, bone and other dense objects that can block the radiation through a
limited exposure to radiation. In addition, X-ray scans can be used for lung infections, pneumonia and
tumors. An automatic prediction of COVID-19 was successfully reported using Chest X-ray images
and a deep convolution neural network based pre-trained transfer models (ResNet50, InceptionV3
and Inception-ResNetV) [71]. These pre-trained transfer models helped to obtain a higher prediction
accuracy for small X-ray dataset. This model has end-to-end structure without manual feature
extraction and selection methods, where the ResNet50 is an effective one among all pre-trained models
in the small dataset (50 COVID-19 vs. 50 Normal).
3.3.2. Computed Tomography
Computed tomography (CT) scan is a computer-assisted medical imaging device which combines
cross-sectional (tomographic) scanned images of specific areas or virtual slices of any organ taken from
different angles producing a 3D view of that particular organ. CT-scan is one of the methods used to
diagnose various abnormalities of the chest (such as pneumonia, lung cancer etc.) [72,73]. Thus, chest
CT-scan is also being used as a fast, painless, non-invasive and accurate auxiliary diagnostic method
in addition to the RT-PCR test for the suspected COVID-19 patient [74–76]. The National Health
Commission of China included the chest CT findings as evidence of clinical diagnosis of COVID-19
for patients in Hubei province at the fifth edition of the Diagnosis and Treatment Program of 2019
New Coronavirus Pneumonia due to the false-negative rate of RT-PCR test for COVID-19 patient [74].
Several groups found chest CT scan more sensitive and better diagnostic tool in comparison to RT-PCR
for COVID-19 detection [75,76]. Recent investigations demonstrated that the CT-scan of COVID-19
patient(s) clearly showed bilateral pulmonary parenchymal ground-glass and consolidative pulmonary
opacities, with a rounded morphology, crazy-paving pattern, linear opacities, and peripheral lung
distribution [77,78]. In contrast, other study did not find any lung cavitation, discrete pulmonary
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nodules, pleural effusions, and lymphadenopathy [77]. Further, high-resolution CT (HRCT)-scan for
the chest is reported to be important tool to help clinicians to diagnose quickly and accurately the
effected lung disease [79]. Artificial Intelligence (AI) and deep learning-based automated CT image
analysis of lung have been also developed to distinguish COVID-19 pneumonia and Influenza-A viral
pneumonia [80–82]. These automated deep learning based methods can produce graphical pattern of a
particular COVID-19 patient which is helpful for clinician to diagnose prior to pathogenic testing [83].
In spite of such clinical diagnostic values, CT scan still fails to come at the forefront of COVID-19
diagnosis due to the following reasons: (i) it is expensive, (ii) it requires technical expertise, and (iii) it
is incapable of distinguishing SARS-CoV-2 pneumonia from other viral pneumonia and hysteresis.
3.4. Autopsy-On Demand
An autopsy report, through examination of a corpse by dissection, is an important source of
information for research purposes to evaluate any disease causing death. Autopsy has been proved to
be hugely beneficial to diagnose emerging and reemerging infectious diseases, like COVID-19 [84–86].
In contrary, several groups raised their concern that the few autopsies have been performed on patients
who died with suspected or confirmed COVID-19 infection especially in the primary epicenters
of pandemic (such as China and Italy) [85,87]. Despite the suggestion by WHO on performing
post-mortem examinations for COVID-19 deaths with following recommended safety procedures,
many Governments including Italy discouraged the practice of autopsy during the period of increasing
number of death and even some scientific report highlighted that the post-mortem examination
does not have any primary diagnostic role, whereas autopsy may still have a clinical role in selected
cases [88,89]. Though based on autopsies, physicians can determine a profound change of the view
of COVID-19 disease not as a pneumonia but a systemic, vascular disease, putatively generated by
autoimmunity [85]. Thus, a strong recommendation was urged to perform full autopsies on patients
who died with suspected or confirmed COVID-19 infection with recommended exceptional biosafety
guidelines to reduce the further spread of potential infection from any corpse.
4. Treatment Modalities
There is currently no clinically proven therapeutic regimen to prevent and eradicate SARS-CoV-2
infection [90]. COVID-19 is being managed by the supportive treatment (oxygenation and ventilation,
conservation fluid management). However, the use of broad-spectrum antibiotics [91]. This section
summarizes various treatment modalities for COVID-19 (Figure 3).
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4.1. Antiviral Drugs
Viral infection is always a major concern for morbidity and mortality in animals and humans
worldwide. Development of antiviral drugs have been always a pressing need to treat such
viral infections. Since the approval of first antiviral drug, idoxuridine in 1963, 90 drugs were
clinically approved to treat nine human infectious diseases (human immunodeficiency virus, HIV;
hepatitis B virus, HBV; hepatitis C virus, HCV; herpesvirus; influenza virus; human cytomegalovirus;
varicella-zoster virus; respiratory syncytial virus; and human papillomavirus) [92]. The antiviral drugs
mostly inhibit the viral development rather than destroying the target pathogen unlike most antibiotics.
A broad-spectrum antiviral is found to be effective against a wide range of viruses based on drug
repurposing strategy [93].
Drug repurposing or drug repositioning is a cost-effective and time-efficient alternative strategy,
which involves the recycle or re-use of clinically approved drugs for new disease instead of searching of
new drugs [94,95]. In contrary to in vitro phenotypic screening of known drugs, in silico/computational
drug repurposing strategy is a hypothesis-driven approach to identify the drugs for the treatment
of any disease using big data analysis [96,97]. The drug-repurposing has been implied for several
human diseases including antiviral drug development against coronavirus [95]. Various groups have
proposed number of drug candidates through drug-repurposing (in vitro and in silico) for COVID-19
treatment [98–101]. WHO focused and initiated the “SOLIDARITY Trial” (announced on 18 March
2020) of four existing antiviral compounds/formulations (Figure 4) to assess their clinical benefit against
COVID-19 [102,103].
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treatment by WHO (announced on 18 March 2020).
Remdesivir, an antiviral compound, which showed activity against multiple variants of
Ebola virus in cell-based assays and rhesus monkey model. Chloroquine (CQ) and its derivative
hydroxychloroquine (HCQ), antiviral compound(s) have been used to treat malaria and amebiasis.
A combination of lopinavir and ritonavir, is co-formulated for HIV-1 treatment. Another combination
of lopinavir and ritonavir plus interferon-beta (LPV/RTV-IFNb) has been approved for the treatment of
relapsing–remitting multiple sclerosis and secondary progressive multiple sclerosis. About 115 clinical
trials were identified by Belhadi et.al., which includes open-label studies (46%), double-blind (13%),
and single blind studies (10%) [104]. They also classified the number of trials (n) and total numbers
of planned inclusions (N) for lopinavir/ritonavir (n = 15, N = 2606), chloroquine (n = 11, N = 1102),
hydroxychloroquine (n = 7, N = 1048), and remdesivir (n = 5, N = 2155).
In contrary, several controversial reports including toxic side effects on these promising
candidates under clinical trial(s) raised some challenging questions for researchers. Those have
been presented below:
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1. A report presents that patients (with symptom duration of 10 days or less) receiving remdesivir
showed clinical improvement than those receiving placebo, but it did not make any statistically
significant clinical benefits [105].
2. An open-label non-randomized clinical trial study demonstrated significant decrease in viral
load and carriage duration in COVID-19 patients receiving hydroxychloroquine (600 mg/day
during ten days). This treatment showed enhanced effects in combination with azithromycin,
but it identified serious methodological flaws [106,107]. Another randomized clinical study did
not make any difference in recovery rates upon hydroxychloroquine treatment in 30 COVID
patients [108]. However, a hype on CQ and HCQ has created drug shortages and affected other
potential treatments (such as for patients with Lupus).
3. There was no significant benefit (clinical improvement) observed with lopinavir–ritonavir
treatment [108]. Mortality and percentages of patients with detectable viral RNA at various time
points were similar in the lopinavir–ritonavir group and the standard-care group. It was also
reported median time to clinical improvement was shorter by one day for lopinavir–ritonavir
group than that observed with standard care.
4.2. Vaccine Development
Vaccination is one of the most effective and preventive medications against various diseases caused
by pathogens (such as virus or bacteria). Currently there are about 25 approved vaccinations available
against various life-threatening diseases, including measles, polio, tetanus, diphtheria, meningitis,
influenza, typhoid, and cervical cancer (https://www.who.int/topics/vaccines/en/). A vaccine typically
contains an agent (weakened or killed forms of any microbe, its toxins, or one of its surface proteins),
which though resembles a disease-causing microorganism, but provides active acquired immunity to
that particular infectious disease [109,110]. An antiviral vaccine helps to boost our natural immune
response to an invading virus by priming it to recognize viral antigens. In general, antiviral vaccines
can be classified as follows: (i) inactive or live-attenuated viruses, (ii) virus-like particle (VLP), (iii) viral
vectors, (iv) protein-based, (v) DNA-based, and (vi) mRNA-based vaccines [110,111]. Like many
other diseases, the vaccine development is not successful and conclusive for coronavirus disease.
Until now, there is no proper vaccine is developed or approved for the treatment of human coronavirus
diseases (such as SARS-CoV and MERS-CoV) [111–113]. Most big pharmaceutical companies also in
the race to develop effective vaccines for CoV infection [112,113]. The existing knowledge on previous
strategies for CoV vaccine developments can benefit the ongoing research as sequence analysis of the
SARS-CoV-2 genome showed close relation to SARS (80%) and to one bat RaTG13 SARS-like CoV (96%)
than to MERS CoV (54%) [112]. Liu et al. [111] reported that 188 patents (mentioned in CAS content
collection) are directly associated with anti-SARS and anti-MERS vaccines (15 patents on inactive
and live-attenuated virus vaccines, 28 patents on DNA vaccines, 21 patents on viral vector vaccines,
13 patents on VLP vaccines, and three patents on mRNA vaccines) with a demonstrated immune
response, which could be a huge boost for COVID-19 vaccine developers. An accelerated evaluation
of next-generation vaccine for COVID-19 has been triggered as soon as the genetic sequence of
SARS-CoV-2 is published on 11 January 2020 [112–115]. As of 28 July 2020, 164 vaccine candidates have
been identified (https://www.who.int/who-documents-detail/draft-landscape-of-covid-19-candidate-
vaccines), of which 25 candidate vaccines are in clinical evaluation (Table 2) and 139 candidate vaccines
are in preclinical stages.
Associated problems and pitfalls are surely a major concern resulting huge roadblock for vaccine
discovery against COVID-19. The pitfalls are many folded, which as follows: (i) antibody-dependent
enhancement (ADE) of viral replication for vaccinated people in future recurrence due to immune
backfiring, (ii) rouge immunization resulting a huge damage on someone’s own immune cells (such as
neutrophil and basophil), (iii) in addition to immune response malfunctioning, three imperatives
of vaccine effort: speed, manufacture and deployment at scale, and (iv) global access for a newly
developed vaccine [116,117].
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Table 2. List of candidate vaccines presently in clinical evaluation for COVID-19 (Source: WHO official
website, data accessed on 28 July 2020).
Platform Type of Vaccine Developer Status
Non-Replicating
Viral Vector ChAdOx1-S
University of
Oxford/AstraZeneca
Phase 1/2: PACTR202006922165132
2020-001072-15
Phase 2: 2020-001228-32
Phase 3: ISRCTN89951424
Inactivated Inactivated Sinovac
Phase 1/2:
NCT04383574
NCT04352608
Phase 3: NCT04456595
Inactivated Inactivated Wuhan Institute of BiologicalProducts/Sinopharm
Phase 1/2: ChiCTR2000031809
Phase 3: ChiCTR2000034780
Inactivated Inactivated Beijing Institute of BiologicalProducts/Sinopharm
Phase 1/2: ChiCTR2000032459
Phase 3: ChiCTR2000034780
RNA LNP-encapsulated mRNA Moderna/NIAID
Phase 1: NCT04283461
Phase 2: NCT04405076
Phase 3: NCT04470427
RNA 3 LNP-mRNAs BioNTech/FosunPharma/Pfizer
Phase 1/2: 2020-001038-36
ChiCTR2000034825
Phase 3: NCT04368728
Non-Replicating
Viral Vector Adenovirus Type 5 Vector
CanSino Biological Inc./Beijing
Institute of Biotechnology
Phase 1: ChiCTR2000030906
Phase 2: ChiCTR2000031781
Protein Subunit Adjuvanted recombinantprotein (RBD-Dimer)
Anhui Zhifei Longcom
Biopharmaceutical/Institute of
Microbiology, Chinese
Academy of Sciences
Phase 1: NCT04445194
Phase 2: NCT04466085
Inactivated Inactivated
Institute of Medical Biology,
Chinese Academy of Medical
Sciences
Phase 1: NCT04412538
Phase 1/2: NCT04470609
DNA DNA plasmid vaccine withelectroporation
Inovio
Pharmaceuticals/International
Vaccine Institute
Phase 1/2: NCT04447781
NCT04336410
DNA DNA plasmid vaccine +Adjuvant
Osaka
University/AnGes/Takara Bio Phase 1/2: NCT04463472
DNA DNA plasmid vaccine Cadila Healthcare Limited Phase 1/2: CTRI/2020/07/026352
DNA DNA Vaccine (GX-19) Genexine Consortium Phase 1/2: NCT04445389
Inactivated Whole-Virion Inactivated Bharat Biotech NA
Protein Subunit
Full length recombinant
SARS CoV-2 glycoprotein
NPs vaccine adjuvanted
with Matrix M
Novavax Phase 1/2: NCT04368988
Protein Subunit RBD-based Kentucky Bioprocessing, Inc Phase 1/2: NCT04473690
RNA mRNA Arcturus/Duke-NUS Phase 1/2: NCT04480957
Non-Replicating
Viral Vector Adeno-based Gamaleya Research Institute
Phase 1: NCT04436471
NCT04437875
Protein Subunit
Native like Trimeric
subunit Spike Protein
vaccine
Clover Biopharmaceuticals
Inc./GSK/Dynavax Phase 1: NCT04405908
Protein Subunit Recombinant spike proteinwith Advax™ adjuvant Vaxine Pty Ltd./Medytox Phase 1: NCT04453852
Protein Subunit
Molecular clamp stabilized
Spike protein with MF59
adjuvant
University of
Queensland/CSL/Seqirus Phase 1: ACTRN12620000674932p
RNA LNP-nCoVsaRNA Imperial College London Phase 1: ISRCTN17072692
RNA mRNA Curevac Phase 1: NCT04449276
RNA mRNA
People’s Liberation Army
(PLA) Academy of Military
Sciences/Walvax Biotech.
Phase 1: ChiCTR2000034112
VLP
Plant-derived VLP
adjuvanted with GSK or
Dynavax adjs.
Medicago Inc. Phase 1: NCT04450004
Protein Subunit S-2P protein + CpG 1018 Medigen Vaccine BiologicsCorporation/NIAID/Dynavax Phase 1: NCT04487210
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Further, new findings and hypotheses stirred up the debate on COVID-19 research making it
difficult as well as relevant not only in therapy but also in producing a life-saving vaccine, without any
risk of generating immunity-based complications.
(i) Molecular mimicry: two independent groups (Lucchese and Flöel; Macario and Cappello)
proposed molecular mimicry as the culprit in determining multi-organ damages (including anosmia,
leukopenia, and vascular damage) in COVID-19 patients [118–120]. Indeed, there are confirmations
that a number of human proteins share common epitopes with SARS-CoV-2 proteins and these epitopes
are highly immunogenic. (ii) Biphasic infection: due to (a) the ability of human coronaviruses to cause
respiratory re-infections, regardless of pre-existing humoral immunity and (b) evidence on circulation
of severe acute respiratory syndrome coronavirus type 2 (SARS-CoV-2) in Italy before the detection of
first COVID-19 case, an hypothesis was given on biphasic infection, the immunological result of a prior
viral infections either by SARS-CoV-2 or different strains of coronaviruses, or potentially even other
respiratory viruses resulting increased susceptibility to more severe forms of COVID-19, following
a secondary infection with SARS-CoV-2 [121]. This theory is sustained by anecdotal clinical reports
of “biphasic infection” and “cytokine storm” through a possible ADE immunological mechanism,
which was already observed with infections sustained by other coronaviruses (such as SARS-CoV and
MERS-CoV) or other viruses (such as West Nile Virus and Dengue).
4.3. Convalescent Plasma (Antibody) Therapy
Convalescent plasma (CP) therapy involves the administration of antibodies to a susceptible
person to prevent or treat an infectious disease providing an immediate immunity [122]. In this therapy,
donated blood from the infected person who’ve recovered from that infection have antibodies in
their blood that can fight against the infection. The CP therapies have been tested since 1890s as a
possible alternative and/or auxiliary treatment including SARS-CoV, Ebola, Influenza A (H5N1) etc.
viruses [123,124]. Additionally, CP therapy did not show any serious and immediate adverse effects in
earlier CoV treatment [125]. The plasma with antibodies is prepared after separation of blood cells
from the donated blood which can be extended to combat against COVID-19. CP therapy has been
generally approved as experimental treatment for patients with critical conditions.
Duan et al. [126] reported potentially improved clinical outcomes for 10 severe COVID-19 patients
with a dose of 200 mL of CP (derived from recently recovered donors with the neutralizing antibody
titers above 1:640) with additional use of antiviral agents and maximal supportive care. This study
confirmed a number of positive outcomes, including, (i) neutralizing antibody level increased rapidly
up to 1:640 in five cases, while for other four cases maintained at a high level (1:640), (ii) increased
oxyhemoglobin saturation within three days, (iii) increase in lymphocyte counts (0.65 × 109/L vs.
0.76 × 109/L), (iv) decreased C-reactive protein (55.98 mg/L vs. 18.13 mg/L), (v) varying degrees
of absorption of lung lesions within seven days, (vi) undetectable viral load in seven patients who
had previous viremia. Additionally, treatment with human immunoglobulin is reported to increase
same-day thrombotic event risk significantly (0.04 to 14.9%) [127]. Transfer of blood substances may
include inadvertent infection with another infectious disease agent and react to serum constituents
resulting immunological reactions such as serum sickness [128]. More high-quality studies, adequate
selection of donors with high neutralizing antibody titers, central blood banking facilities to process
the donated serum, efficient serological and virological assays, production and the use of CP according
to precise ethical and controlled conditions are needed for implementing this therapy further.
4.4. Auxiliary Blood Purification Treatment
Latest studies showed that ACE2, the key functional receptor of SARS-CoV-2, is highly expressed
in kidney (nearly 100 times higher than in lung) resulting it to be a main target organ for SARS-CoV-2
attack [129]. Thus, novel coronavirus infections hugely damage the kidney of any severe COVID-19
patient suffering from an immunological damage due to a cytokine storm, the imbalance of
pro-inflammatory and anti-inflammatory factors. Thus, auxiliary continuous blood purification
Diseases 2020, 8, 30 15 of 30
could be an essential technology to take care of inflammatory factors, cytokine storm, electrolyte
imbalance, and acid-base balance for any COVID-19 patient resulting a reduced renal work-load and a
possible recovery of renal function [130,131]. At present, extracorporeal blood purification technology
is supplied for severely ill patient with novel coronavirus pneumonia as an auxiliary treatment to
improve condition [132].
4.5. Traditional, Complementary, and Alternative Medicine
There is an increasing awareness, tendency, and agenda to use traditional (T) medicine (indigenous
health traditions) and complementary and alternative medicine (CAM) (methods outside the biomedical
mainstream, particularly in industrialized countries). Globally, half the population uses T/CAM as
a preventive measure [133,134]. The National Center for Complementary and Integrative Health
(NCCIH) of the National Institute of Health (NIH), USA, has included various medical methods under
the umbrella term CAM, such as homeopathy, naturopathy, Ayurveda, medicinal systems, and products
originating from traditional medicine [135]. Further, herbalism, aromatherapy, acupuncture, massage,
and reflexology are also various name and forms among the most popular branches of CAM [134].
The potential use of CAM (sometimes along with conventional medicine) has been reported to be
efficient therapeutic strategy against several virus associated diseases such as influenza, dengue,
Japanese encephalitis, hepatitis C, zika, and HIV [134–136]. Considering the efficacy of CAM against
coronaviruses with minimal reported adverse effects on host cells, Ministry of Ayush (Ayurveda, Yoga
& Naturopathy, Unani, Siddha and Homoeopathy), Government of India, recommended scientists,
researchers and clinicians to pursue research and use of Indian herbal drugs on COVID-19. Through
a memorandum, Government of India is now trying to utilize the Ayurveda, Siddha, Homeopathy,
and Unani system of medicine including prophylactic measures, intervention during quarantine,
asymptomatic and symptomatic cases, public health research, survey, laboratory-based research etc.
(https://www.ayush.gov.in/). Indian traditional medicinal systems, one of the oldest treatments in
human history (existed nearly 5000 years ago witnessed and scripted in ancient literature), played a
significant role in encountering global health due to its antiviral, anti-inflammatory and antioxidant
properties [137,138]. Such a traditional branch of science could be a potential option against COVID-19
because of its proved efficacy not only in treatment but also in preventive strategy for several diseases,
including respiratory viral infections through immunity boosting, rejuvenating lifestyle, and dietary
management [137,138]. AYUSH recommended selected traditional drugs for COVID-19 as follows:
http://ayush.mp.gov.in/sites/default/files/CORONA%20ADVISORY_3.pdf.
Furthermore, Vimalanathan et al. reported strong activity of several Indian medicinal
plants in Tamil Nadu against mouse corona virus (a surrogate for human SARS-CoV), which are
as follows: “Gymnema sylvestre R. Br. (Asclepiadaceae), Pergularia daemia (Forsskal) Chiov.
(Asclepiadaceae), Sphaeranthus indicus L. (Asteraceae), Cassia alata L. (Caesalpiniaceae), Evolvulus
alsinoides L. (Convolvulaceae), Clitoria ternatea L. (Fabaceae), Indigofera tinctoria L. (Euphorbiaceae),
Abutilon indicum G. Don. (Malvaceae), Vitex trifolia L. (Verbenaceae), Clerodendrum inerme
(L.) Gaertn (Verbenaceae), and Leucas aspera Spr. (Lamiaceae)” [139]. Traditional Chinese
medicine (TCM) is also recently being included as one of the treatment modalities in China for
COVID-19. Previous record on efficacious TCM against respiratory tract infectious diseases, such as
Lianhua Qingwen capsules (exerts independent antiviral effects) and ShuFeng JieDu capsules
(synergistic antiviral effects with Western medicine) on influenza viruses, has encouragd the
practice of TCM against COVID-19 [140,141]. Wang et al. [142] reported massive improvement
for four COVID-19 patients as a result of combination therapy including Chinese and Western
antiviral medicine, where they used lopinavir/ritonavir (Kaletra®), arbidol, and Shufeng Jiedu
Capsule (SFJDC) with necessary supportive care. However, lack of high-quality research, standard
clinical trials, sufficient research articles, clear mechanism of action, rigorous population studies,
prospective business model are also urgently required to establish the therapeutic effect and
implementation of T/CAM among mass population. In spite of some emphatic results through
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traditional, complementary, and integrative products, practices, and practitioners against COVID-19,
North American and European governments are keeping their silence on these practices (https:
//www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html) and rather warned of
possible harm and overselling (https://www.fda.gov/news-events/press-announcements/coronavirus-
update-fda-and-ftc-warn-seven-companies-selling-fraudulent-products-claim-treat-or). John Weeks,
Editor-in-Chief of The Journal of Alternative and Complementary Medicine, mentioned this double
standard attitude as he pointed out that “no practices have definitive evidence for benefit against
COVID-19, yet providers with other stripes are using experimental practices and off-label drugs every
day in their desperate to ease patient suffering and elicit hope” [143].
5. Preventive Modalities
Prevention is the utmost important strategy to fight against COVID-19 in the present situation.
Several preventive measurements are taken to reduce the spread and transmission of the COVID-19
infection. This is classified as follows (i) contact tracing, (ii) sharing or proper dissemination of
information, (iii) precautionary measurements (Figure 5).
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5.1. Contact Tracing and Share of Information
Track, trace, and share of the information on COVID-19 are major preventive steps to stop
spreading of SARS-CoV-2. A thorough, quick, and updated report should be always available
covering various information (such as number of infected cases, casualties, regions affected in each
country etc.) on easily accessible platforms. The promotion of “Data Science” or Big Data and data
driven interdisciplinary research areas has helped a lot to control such global infectious disease or
epidemics through extensive surveillance, sharing of epidemiological data, and patient monitoring [144].
Benefits of big data with technological advancement has facilitated the communication among regional,
national and international healthcare agencies to monitor future host adaption, viral evolution,
infectivity, transmissibility, morbidity, mortality, mental health impact and psychological effects due to
COVID-19 epidemic. Here we have mentioned some authentic responsible agencies and tools along
with several controversies aroused from the use of data science as follows:
5.1.1. Responsible Agencies and Devices
WHO: WHO is providing a daily “Situation Report” as an update on COVID-19 pandemic
(https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports), where WHO
receives the data from national authorities.
Worldometer: Worldometer is a free reference website (managed by an international team of
developers, researchers, and volunteers) that provides counters and real-time statistics on various
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topics such as world population, government, economics, society, media, environment, food, water,
energy, and health (https://www.worldometers.info/). Now the data in website is currently available
in 35 languages and will be available in 11 more languages soon (https://www.worldometers.info/
languages/, accessed on 1 May 2020). This reference website belongs to a United States of America
(USA)-based digital company Dadax (http://dadax.com/). Presently, this website is being used quite
popularly to provide various statistics (graphs, countries, death, symptoms, incubation, transmission,
news) on COVID-19 pandemic around the world (https://www.worldometers.info/coronavirus/)
and the data is also trusted and used by several agencies including government organization of
various countries.
Mobile phones & COVID-19 Apps: The speed and ease of communication is the heart of
management to control the spread of any infectious diseases as it helps to build extensive surveillance,
share of epidemiological data, and patient monitoring. Mobile phone or especially smartphone
with the help of various mobile apps (software application) can improve this purpose due to its
speedy connectivity, computational power, remote access, electronic reporting, epidemiological data
basing, real-time geospatial information, digitized process of contact tracing, more complete and
shareable records, enhanced coordination among regional, national and global health agencies [145,146].
A past experience on using smartphones for geospatial tracking of infectious diseases such as HIV,
Ebola, and tuberculosis has helped to build these devices further to control COVID-19 epidemics
by implementing healthcare strategies, and improving general awareness among masses [147–149].
Further, smartphone embedded point-of-care testing and self-reporting facilities has helped to reduce
risk of contracting COVID-19 as these help actual and suspected patients with mild symptoms
under self-quarantine to report remotely without going to any overcrowded hospital or healthcare
centers [150,151]. WHO launched mobile app (https://github.com/WorldHealthOrganization/app) to
accurately track and trace COVID-19 cases. There are also several official contact tracing apps available
for the citizen of various countries to inform a person’s own health to help governments in strategic
control (e.g., “Aarogya Setu” in India, “Covid Watch” in USA, “NHS COVID-19” in UK, "Alipay Health
Code" in China, etc.,).
5.1.2. Duel in Data
Despite huge effort and help from data science, dueling in data caused also deviation, divisive
and neglecting attitude regarding COVID-19. This further facilitates the spread of pandemic, shifting
epicenters, more casualties, economic loss and so many other secondary problems created due to
pandemic. Here we have summarized some problems associated with data handling.
Reproductive number: The basic reproduction number (R0), an indication of the transmissibility
of a virus in infectious disease epidemiology, has been used to represent the average number of
new COVID-19 infections generated by an infectious person in a totally naïve population [152]. It is
estimated that (i) the number of infections is likely to increase for R0 > 1, and (ii) transmission is
likely to die out for R0 < 1. Thus, a true estimation of R0 can be beneficial in terms of prevention of
any infectious disease. Liu et al. estimated higher reproductive number of COVID-19 compared to
SARS coronavirus and also reported that the average reproductive number for COVID-19 (R0 ~ 3.28) is
considerably higher than that of WHO estimate (R0 = 1.95) [153]. They mentioned that the current
estimates of R0 for COVID-19 are possibly biased due to insufficient data and short onset time.
“Risk of death” measurement: Estimation of the case fatality risk or the risk of death among
positive cases is a common epidemiological practice to measure the severity of infection for a given
disease. Kobayashi et al. [154] mentioned several key epidemiological problems for assessment of the
severity of COVID-19 as follows—(i) “division of the cumulative number of deaths by that of cases
tends to underestimate the actual risk because deaths that will occur have not yet observed, and so the
delay in time from illness onset to death must be addressed”; (ii) “the observed dataset of reported
cases represents only a proportion of all infected individuals and there can be a substantial number of
asymptomatic and mildly infected individuals who are never diagnosed”; (iii) “ascertainment bias
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and risk of death among all those infected would be smaller when estimated using shorter virus
detection windows and less sensitive diagnostic laboratory tests”. They further suspected that the
total number of reported COVID-19 infections will be underestimated due to many undetected mild or
asymptomatic cases that go.
Open data source: In this fight against COVID-19, an open data source is a big step forward
in the age of Big Data. Amaro et al. [155] urged to make an effort through a “Community
Letter” for sharing bimolecular simulation data on COVID-19 to help and improve connection
and communication among scientists and investigators working on simulation, experimental and
clinical data. They committed to share methods, models, and results of their study openly and
quickly to test findings, ensure reproducibility, test significance, eliminate dead-ends, and accelerate
discovery on COVID-19 applications. They committed to use preprint servers such as arXiv, bioRxiv,
and ChemRxiv, open access data repositories such as Zenodo, an open data sharing platforms for
models and trajectories such as the Molecular Sciences Software Institute (MolSSI) SARS-CoV-2
Biomolecular Simulation Data and Algorithm Store, the Open Science Framework, the European Open
Science Cloud and several other agencies. They also make an appeal and encourage others for similar
best practices on open data efforts in other research areas to prevent COVID-19.
Cyber-attack: In this grave situation due to COVID-19, the revolutionized advancement of
information and communications technology is a crucial weapon to control the healthcare infrastructure
in addition to businesses, deliveries of food and essential items to remote places, online grocery shopping
etc. But there is a growing concern due to an increasing report of malicious attacks on information and
communications technology during COVID-19 as attackers find this an opportunity for financial gains
and promoting evil intents. A 220 times increase in spam email and 260% in malicious URLs have been
reported from February to March 2020, in which the United States is found to be the epicenter for such
targets [156]. Healthcare systems, government and media outlets, financial services are some of most
important organization and industries, which are identified at the risk of cyber-attack [157]. This team
has identified the top ten such deadly cybersecurity threats amid COVID-19 pandemic, which are
as follows—(i) distributed denial of services (DDoS) attack, (ii) malicious domains, (iii) malicious
websites, (iv) malware, (v) ransomware, (vi) spam emails, (vii) malicious social media messaging,
(viii) business email compromise, (ix) mobile threats, and (x) browsing apps. The Worldometer website
was reported under cyber-attack in March 2020 and was then hacked a few days later, resulting
in incorrect information (dramatic rise on COVID-19 statistics in Vatican City) for approximately
20 min (https://www.euroweeklynews.com/2020/03/16/false-report-of-900k-dead-in-vatican-city-last-
night-i-nearly-fell-off-my-chair-reading-it/). Use of contact tracing COVID-19 apps also raised some
security and privacy concern as it keeps personal database of any individual [158,159]. Thus there is a
continuous debate on this issue and demand of more reliable apps among mass population, whereas
governments are trying to make it a mandatory use as experts shown their confidence about these
apps [160].
Social media activism: Containment measures are primary guideline to tackle the novel
coronavirus (COVID-19) pandemic. Due to moving out of physical public spaces, people are using
online platforms as even more prominent and powerful tools to communicate social discussion and
understand the unprecedented global crisis. However, Ferrara reported after tracking and studying
43.3M real-time English tweets about COVID-19 (the large-scale data was collected since January 21,
2020, the day the first COVID-19 case was reported on US soil to the dataset up to 12 March 2020,
the day before the United States government announced the state of national emergency due to the
COVID-19 pandemic) that the information on social media platforms are populated by bots, automated
accounts [161]. This study provided the evidence that high bot score accounts are used to amplify
certain topics of discussion at the expense of others, such as (i) promotion of political conspiracies and
divisive hashtags alongside with COVID-19 content, and (ii) enabling participatory activism to shed
light on issues that may otherwise be censored in China. Thus, this study demands more nuanced and
regulated discussion on social media platforms on COVID-19.
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5.2. Precautionary Measurements
Behavioral changes and use of protective gears have been prescribed as the first and foremost
precautionary step to stop the spread of SARS-CoV-2. Gradual understanding of the transmission of
this virus and previous experience on successful behavioral imposition to control other epidemics
such as AIDS (changes in sexual behavior, condom promotion, and government interventions) has
helped a lot in that direction. Though more efficient behavioral changes in daily lifestyle requires
better understanding and proper implementation of the rules with time on COVID-19 transmission.
Awareness on the risks from exposure level to respiratory droplets, airborne virus, contamination
level from surfaces, concentration of transmission, incubation period, infectivity even before onset of
symptoms in the incubation period, transmission from asymptomatic people will definitely be helpful
to understand (i) behavioral changes and precautionary guidelines and (ii) use of protective gears.
Further use of telemedicine and robot can also play a crucial role as precautionary steps to combat
against such infectious diseases.
Behavioral changes and precautionary guidelines: Knowledge on COVID-19 has helped to
set precautionary guidelines in our day to day lifestyle. Various health agencies such as WHO,
The Centers for Disease Control and Prevention (CDC), National Public Health Institute of the
United States and many more recommended following general measures to prevent the spread of
COVID-19—(i) complete washing of hands often using an alcohol-based hand sanitizer to kill the
SARS-CoV-2, (ii) avoid close contact, (iii) cover mouth and nose with a cloth or mask (e.g., N95
respirators) in public places, (iv) cover coughs and sneezes, (ii) avoid touching eyes, nose and mouth
when outside, (iii) avoid travelling or gathering in crowded places, (iv) clean and disinfect frequently
touched surfaces, (v) women with infants are encouraged to breastfeed their babies to enhance
their immunity (https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/prevention.html,
https://apps.who.int/iris/handle/10665/330376). In addition to hand hygiene practices, WHO also has
given proper guidelines for 1. sanitation and plumbing of COVID-19 hospitals, quarantine centers;
2. toilets and the handling of feces of COVID-19 patients; 3. safe management of health care waste;
4. environmental cleaning and laundry at healthcare facilities; 5. safe disposal of greywater or
water from washing personal protective gears, surfaces and floors; 6. safe management of dead
bodies; 7. management of waste generated at home; 8. treatment and handling requirements for
excreta (https://www.who.int/publications-detail/water-sanitation-hygiene-and-waste-management-
for-the-covid-19-virus-interim-guidance). The guidance from National Center for Complementary and
Integrative Health (NCCIH), National Institutes of Health prescribed a “healthy waiting” in life style,
which includes social distancing (or physical distancing), mild exercise, stress reduction, restriction
on smoking and alcohol (https://www.nccih.nih.gov/health/in-the-news-coronavirus-and-alternative-
treatments). To prevent such health crisis and boost immunity with special reference to respiratory
health, Ministry of AYUSH, India recommended the following self-care guidelines in daily lifestyle
(https://www.mohfw.gov.in/pdf/ImmunityBoostingAYUSHAdvisory.pdf):
Further, home isolation or quarantine of suspected cases and those with mild illnesses have
been entailed as prevention to reduce the burden on COVID-19 hospitals for severe cases [162]. As a
preventive measurement, countries have imposed not only inter nation lockdown, but also total or
partial lockdown inside their territory to minimize transmission from foreign nationals, social gathering
and day to day activity [163]. Lockdown area are also classified based on infection progression and
hotspot are also indicated to inform mass about the containment zone. Thermal screening has become
a common strategy to track the probable symptomatic cases at various juncture of transportation.
It is obvious that such changes in daily life of general population and healthcare unit need more
time to cope with. Implementation of such changes is challenging in short time against rapid infectious
nature of COVID-19. According to the psychiatrists and allied professionals, COVID-19 pandemic
and such forceful precautionary guidelines created subsyndromal mental health at multiple levels
in the general population, among healthcare workers, and in vulnerable populations resulting the
symptoms of anxiety and depression, self-reported stress, insufficient sleep [164]. Also, it is surely very
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conflicting to maintain balance between economy and public health during such long lockdown [165].
Every section of society specially those belonging to lower socio-economic state is being affected
economically sooner or later due to such crisis, which create a desperation to neglect such imposed
rules on mass population resulting further increase of COVID-19 cases.
Protective gears: Various protective gears are playing an important role to stop the spread pandemic.
Frontline healthcare professionals, in addition to healthy mass population are at a huge risk in COVID-19
transmission from patients, suspected cases. As of 12 April 2020, more than 2200 healthcare workers
including doctors have been infected (https://health.economictimes.indiatimes.com/news/industry/who-
says-over-22000-healthcare-workers-across-52-countries-infected-by-covid-19/75107238). In 2002 during
the SARS outbreak, nearly 21% of those virus-affected were healthcare workers [166]. This is an even
more warning situation as it is important that the healthcare workers should be protected from infection
to ensure uninterrupted medical facility and to prevent virus transmission to other patients. Thus, use
of protective gears such as Personal Protective Equipment (PPE) kits, mask (tested N95 respirators),
gloves and goggles are important accessories for healthcare professionals, whereas for mass population
mask (more specifically N95 mask) is foremost important along with other protective guidelines.
Suddenly, very high demand of such protective gears resulted a huge shortage worldwide,
which needs a huge workforce to support healthcare facilities in this crisis. Additive manufacturing
(i.e., 3D printing), an eminent technology for medical device preparation, came out as an innovative
solution for COVID-19 protective gears production with the help of other embedded technologies such
as—(i) antimicrobial polymers and nanoparticles for making PPE, (ii) angiotensin-converting enzyme
2 coated nanoparticles containing respiratory masks, chewing gums and nasal filters (iii) preparation
of recyclable decontaminating nanofiber filtered face masks, etc. [167,168]. These ideas will surely be
advantageous to prepare more effective protective gears for managing such pandemic, though further
research is needed to implement such efforts to market.
Telemedicine: With the advancement of telecommunication technology, telemedicine has emerged
as medical activity involving a doctor-patient distant interaction through telecommunication, which
have been interchangeably known as telehealth (more politically correct term) or online health and
e-health (fashionable term) [169]. Such telecommunication-based remote medical health facility is
surely advantageous against any infectious disease outbreak and thus it is recommended by various
health agencies for COVID-19 as it (i) reduces person-to-person contact by obeying social distancing,
(ii) maintain balance in facilities with limited workforce, (iii) evolves as an alternative cost effective
health provider in comparison to traditional home visit [169–171]. In spite of a promising future and
willingness to use telehealth among patients, telemedicine suffers from various disadvantageous due
to (i) less scope outside of emergency situations, (ii) clinician unwillingness and low acceptance among
patients, (iii) problem with reimbursement, (iv) organization of the healthcare system.
Robotic Gesture: Robots already shown a huge potential as medical device for diagnosis to
surgery including pediatric airway operation, oropharyngeal cancer operation etc. [172,173]. In similar
fashion, to combat infectious epidemics like COVID-19, robots can play pivotal roles due to its abilities
as follows—(i) large area cleaning and disinfection of contaminated surfaces (such as using UV light
devices), (ii) diagnosis by automated or robot-assisted nasopharyngeal and oropharyngeal swab or
blood testing, (iii) patient care by delivering medications and food to infected/suspected persons under
quarantine, (iv) measuring vital signs, (v) assisting controls on transportation of mass population (such
using thermal sensors and vision algorithms), (vi) help in telemedicine, (vii) facial tracking of any
individual already having infection as a process of contact tracing, (viii) navigation in high-risk areas
for sample transfer as well as delivery of medicines using autonomous drones or robot-assisted ground
vehicles [174,175]. Such robot-assisted strategy to control epidemic may speed up the process, reduce
the risk of infection specially for frontline health care professionals, and increase workforce (Figure 6).
Though despite such help in clinical care, logistics and reconnaissance, proper deployment of robots
may face some problem due to privacy and security, incompatible diagnosis with the mutation of virus.
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6. Conclusions and Future Perspectives
In conclusion, this article presented the current progress of four primary and important sphere of
research in the battle against COVID-19 pandemic, which are knowledge of the biological properties of
virus, diagnostic modalities, treatment modalities, and prevention modalities. The huge development
and deployment of advanced level of research and technology has helped to improve severely affected
the global health condition due to COVID-19. A prior knowledge on previous viral outbreaks and
pandemic has really helped researchers, health agencies and administrations a lot in response to
COVID-19. In spite of such a plethora of research, the progress was hampered in many areas due
to conflicting views and controversies about COVID-19. Several such grey areas in transmission,
best diagnostic methods with no false positive reports, possible treatment outcome, contact tracing,
precautionary steps, proper public health management and many other fields has shattered the progress
resulting a chaos and crisis in public health and economy. Despite the conflict, differences in opinions
are an important part of any constant progress. Thus, these conflicting views have helped the field
to grow and will create unprecedented opportunities further solving several unresolved questions.
Governments should encourage and endorse innovative research ideas to beat such pandemics,
not only in basic research and biomedicine, but also in engineering, information technology and many
unknown corners to get a marketable solution in spite of such controversies. In search of proper
treatment, comparatively well-structured diagnosis and prevention are two important armors against
COVID-19 with the help of knowledge on biological properties of SARS-CoV-2. We hope that with time,
more accurate cumulative knowledge will dissipate the ambiguity about COVID-19 and translational
research will help to restore the public life to normalcy. In that aspect, our review would be a huge
boost to address the progress amid controversies on a single platform against COVID-19.
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